Difference between revisions of "Team:SDU CHINA"

 
(99 intermediate revisions by the same user not shown)
Line 2: Line 2:
  
 
<html>
 
<html>
 +
<head>
 +
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
 +
<title>SDU_CHINA</title>
  
−
<div class="square"></div>
+
<style>
−
    <div  class="logo"><img src="https://static.igem.org/mediawiki/2017/4/40/LOGO.png" style="width:140px;height:140px;"></div>
+
.bottom{position:relative;text-align:center}
−
    <div><img src="https://static.igem.org/mediawiki/2017/d/d6/SDU_main_title.png" style="z-index:0;width:60%;top:100px;left:300px;position:relative;z-index:1"></div>
+
.bottom .bar{width:100%;height:70px;top:0px;background-color:#f6f6f6;display:absolute;z-index:2;position;fixed}
−
    <div><img src="https://static.igem.org/mediawiki/2017/a/ab/SDU_home_keyboard.png" style="width:60%;position:relative;top:120px;left:250px"></div>
+
.bottom .bg{z-index:-2;display:block}
 +
.bgg{z-index:-2;display:block;positon:relative}
  
 +
.abstract{margin:5em 20% auto 20%;position:relative}
 +
.abstract .title{position:relative;margin:0 auto auto 0;color:#0172b4;font-family:Arial, Helvetica, sans-serif;font-size:30px}
 +
.abstract .content{margin:0 auto;letter-spacing:0.02em;word-spacing:0.2em;font-family:Segoe, "Segoe UI", "DejaVu Sans", "Trebuchet MS", Verdana, "sans-serif";font-size:1.2em;word-wrap: break-word ;position:relative;text-indent:2em;text-align:left}
 +
.video{text-align:center;z-index:2;positon:relative}
 +
.foot{margin:10% auto auto auto}
  
−
<div class="abstract" >
+
</style>
−
    <div class="title"><b>Abstract</b></div>
+
</head>
−
    <div class="content"><p>Non-small cell lung cancer (NSCLC) is the
+
 
−
    leading cause of cancer-related death among the world with low
+
<body>
−
    overall survival rate. In NSCLC, immunotherapy has been indicated
+
<div class="bottom">
−
      as a potential therapy for treating in situ solid tumor. Previous
+
 
−
      research has indicated that tumor cells can express programmed
+
 
−
      death-1 ligand (PD-L1) to diminish T-cell effector functions and
+
<div class="bg"  >
−
        therefore to achieve immune escape. In our project, gene edition
+
<img src="https://static.igem.org/mediawiki/2017/4/4c/Bg.jpeg" style="width:100%;height:auto" style="width:100%;height:auto">
−
        will be incorporated with immunotherapy to eradicate the immune
+
−
        escape occurred in NSCLC. By constructing plasmid with
+
−
        Crispr-Cas 9 system targeting the gene coding for PD-L1, the
+
−
          expression of PD-L1 will be inhibited to restore immune system
+
−
          supervision. To ensure the biosafety, another plasmid with
+
−
          Crsipr-Cas 9 system to cut off the housekeeping gene of two
+
−
          plasmids will be also constructed to suicide both plasmid when
+
−
            PD-L1 expression was not detectable. Better therapeutic effects of
+
−
            immunotherapy to conquer the NSCLC are hoped to be achieved.</p></div>
+
 
</div>
 
</div>
  
−
<br> <br> <br> <br>  <br> <br> <br> <br> 
+
<div class="c"><img src="https://static.igem.org/mediawiki/2017/9/92/Abstract.jpeg" style="width:100%;height:auto"></div>  
  
  
−
<div>
+
 
−
  <div class="foot">
+
<div class="video" style="background:url('https://static.igem.org/mediawiki/2017/5/55/Bggg.jpeg');background-size:100%;padding-top:12em;height:480px;background-repeat:none">
−
  </div>
+
<video src="https://static.igem.org/mediawiki/2017/1/10/Video.mp4" width="48%" controls="controls">
 
</div>
 
</div>
  
 +
 +
<div class="foot"><img src="https://static.igem.org/mediawiki/2017/0/04/Sponsor.jpeg" style="width:80%;height:auto;margin-top:-5em"></div>
 +
<br><br>
 +
<div class="footest"><img src="https://static.igem.org/mediawiki/2017/c/c0/Foot.jpeg" style="width:100%;height:auto"></div>
 +
 +
</div>
 +
</body>
 
</html>
 
</html>

Latest revision as of 05:07, 31 October 2017

SDU_CHINA